Caraco Pharmaceutical continues on its forward roll with another FDA approval. This one is for the manufacture of lipizide/metformin hydrochloride tablets, a generic version of Bristol-Myers Squibb’s Metaglip.
Excerpt:
Sales of Metaglip and other generic versions accounted for $25 million
in sales for the 12 months ending in September, Caraco said in a news
release this week.
Read the entire article
here.